F-18 Tetrafluoroborate PET/CT Scans to Find Differentiated Thyroid Cancer
Compares a new PET/CT scan with standard FDG PET/CT in thyroid cancer follow-up.
Plain-language title generated from the registry record
Registry title: F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Key facts
- Where
- Ankara, TürkiyeSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had surgery and radioactive iodine treatment for differentiated thyroid cancer and now have rising Tg and/or ATg blood levels, to compare two PET/CT scans for finding tumour spots.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Differentiated thyroid cancer treated with surgery and radioactive iodine, with elevated serum Tg and/or ATg levels during follow-up
- Earlier treatment
- Must have had surgery for differentiated thyroid cancer and radioactive iodine therapy
- Biomarker or test result
- Elevated serum Tg and/or ATg levels; I-131 whole-body scan negative or equivocal
Main reasons for not taking part
- Under 18 years of age
- Pregnancy or breastfeeding
- Cannot give written informed consent
Read by machine on 13 November 2026.
Where in Türkiye
- Ankara University Medical School Nuclear Medicine DepartmentAnkara, TürkiyeContact: Mine Araz, Assoc.Prof.Dr.Taking people
- Hacettepe University Medical School Nuclear Medicine DepartmentAnkara, TürkiyeContact: Murat Fani Bozkurt, Prof.Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ankara University
- Trial code
- NCT07436455
- Record updated
- 27 February 2026
- Original description
In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity.Read full original descriptionShow less
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity.
F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies.
The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy.
The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.
Inclusion: Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy; Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up; Negative or equivocal I-131 whole-body scan findings; Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] performance status); Giving written informed consent.
Exclusion: Failure to provide written informed consent; Age under 18 years; Pregnancy or breastfeeding.